Abstract
Background
A long-term projection model based on nationally representative data and tracking disease progression across Alzheimer’s disease continuum is important for economics evaluation of Alzheimer’s disease and other dementias (ADOD) therapy.
Methods
The Health and Retirement Study (HRS) includes an adapted version of the Telephone Interview for Cognitive Status (TICS27) to evaluate respondents’ cognitive function. We developed an ordered probit transition model to predict future TICS27 score. This transition model is utilized in the Future Elderly Model (FEM), a dynamic microsimulation model of health and health-related economic outcomes for the US population. We validated the FEM TICS27 model using a five-fold cross validation approach, by comparing 10-year (2006–2016) simulated outcomes against observed HRS data.
Results
In aggregate, the distribution of TICS27 scores after ten years of FEM simulation matches the HRS. FEM’s assignment of cognitive/mortality status also matches those observed in HRS on the population level. At the individual level, the area under the receiver operating characteristic (AUROC) curve is 0.904 for prediction of dementia or dead with dementia in 10 years, the AUROC for predicting significant cognitive decline in two years for mild cognitive impairment patients is 0.722.
Conclusions
The FEM TICS27 model demonstrates its predictive accuracy for both two- and ten-year cognitive outcomes. Our cognition projection model is unique in its validation with an unbiased approach, resulting in a high-quality platform for assessing the burden of cognitive decline and translating the benefit of innovative therapies into long-term value to society.
Funder
National Institute on Aging
Publisher
Public Library of Science (PLoS)
Reference39 articles.
1. 2019 Alzheimer's disease facts and figures
2. Alzheimer’s disease drug development pipeline: 2019.;J Cummings;Alzheimer’s & Dementia: Translational Research & Clinical Interventions,2019
3. Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective.;B Dunn;JAMA Internal Medicine.,2021
4. The End of the Beginning of the Alzheimer’s Disease Nightmare: A Devil’s Advocate’s View.;A. Wimo;Journal of Alzheimer’s disease: JAD.,2018
5. Preparing the health-care system to pay for new Alzheimer’s drugs.;P-J Lin;Alzheimer’s & Dementia.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献